These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32680520)

  • 1. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
    Van Hout MC; Crowley D; McBride A; Delargy I
    BMC Fam Pract; 2018 Jun; 19(1):103. PubMed ID: 29960593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Constructing a Community-Based Telemedicine Program for People With Opioid Use Disorder During the COVID-19 Pandemic: Lessons Learned and Implications for Future Service Delivery.
    Høj SB; de Montigny C; Chougar S; Léandre R; Beauchemin-Nadeau MÈ; Boyer-Legault G; Goyette A; Lamont SK; Bruneau J
    JMIR Public Health Surveill; 2023 Jul; 9():e39236. PubMed ID: 37494097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis.
    Durand L; Boland F; Harnedy N; Delargy Í; Scully M; Bourke M; Ebbitt W; Otero Vázquez M; Keenan E; Cousins G
    J Subst Use Addict Treat; 2023 Jun; 149():209029. PubMed ID: 37003538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scoping review protocol: the use of telemedicine in providing opioid agonist treatment and related psychosocial supports.
    Crowley D; Homeniuk R; Delargy I
    BMJ Open; 2020 Dec; 10(12):e040556. PubMed ID: 33277286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
    Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
    Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids: The Forgotten Epidemic?
    Price S
    Tex Med; 2020 Oct; 116(10):32-35. PubMed ID: 33126270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "You'll come in and dose even in a global pandemic": A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic.
    Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Hayllar J; Grebely J; Marshall AD
    Int J Drug Policy; 2023 Apr; 114():103998. PubMed ID: 36907071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.
    Eibl JK; Gauthier G; Pellegrini D; Daiter J; Varenbut M; Hogenbirk JC; Marsh DC
    Drug Alcohol Depend; 2017 Jul; 176():133-138. PubMed ID: 28535455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi study.
    Durand L; Keenan E; Boland F; Harnedy N; Delargy Í; Scully M; Mayock P; Ebbitt W; Vázquez MO; Corrigan N; Killeen N; Pate M; Byrne P; Cousins G
    Int J Drug Policy; 2022 Aug; 106():103768. PubMed ID: 35738029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying and managing osteoporosis before and after COVID-19: rise of the remote consultation?
    Paskins Z; Crawford-Manning F; Bullock L; Jinks C
    Osteoporos Int; 2020 Sep; 31(9):1629-1632. PubMed ID: 32548787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Virtual Fracture Clinics During the COVID-19 Pandemic a Potential Alternative for Delivering Fracture Care? A Systematic Review.
    Murphy EP; Fenelon C; Murphy RP; O'Sullivan MD; Pomeroy E; Sheehan E; Moore DP
    Clin Orthop Relat Res; 2020 Nov; 478(11):2610-2621. PubMed ID: 32657810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
    Narayan A; Balkrishnan R
    Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
    Lehmann K; Kuhn S; Schulte B; Verthein U
    Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovation During COVID-19: Improving Addiction Treatment Access.
    Samuels EA; Clark SA; Wunsch C; Jordison Keeler LA; Reddy N; Vanjani R; Wightman RS
    J Addict Med; 2020; 14(4):e8-e9. PubMed ID: 32404652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
    Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
    J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.